Pharmalot

Pharmalot

PhRMA sues Oregon over drug pricing transparency laws, calling them ‘unconstitutional’

By Ed Silverman

Pharmalot

Activists say a patent office lawyer’s tweets showed ‘bias’ in favor of Gilead in HIV drug case

By Ed Silverman

Pharmalot

Pharmalittle: Pharma ad spend skyrockets to defeat drug pricing bill; many antibiotic prescriptions are inappropriate

By Ed Silverman

Pharma

Pharmalittle: Drug factories ‘dump it down the drain’; breast cancer drug picked up by AstraZeneca shrinks tumors

By Elizabeth Cooney

Pharmalot

GAO finds ongoing problems with FDA inspections of foreign drug facilities

By Ed Silverman

Pharmalot

Pharmalittle: A record-setting year for biopharma M&A; Pelosi tries to stem revolt over drug pricing bill

By Ed Silverman

Pharma

Pharmalittle: Republicans have new drug pricing proposal; Sanofi and Merck buy cancer drug companies

By Ed Silverman

Pharmalot

Lawmakers ask HHS for greater oversight of patient assistance programs

By Ed Silverman

Pharmalot

More hospital drug spending is going toward cancer immunotherapies

By Ed Silverman

Pharmalot

Up and down the ladder: The latest comings and goings

By Ed Silverman

Pharmalot

Pharmalittle: Retail prices for drugs edged down last year; Biogen Alzheimer’s data prompt skepticism

By Ed Silverman

Pharmalot

Activists seek to block a Gilead patent extension on a lucrative HIV drug

By Ed Silverman

Pharmalot

Bribing doctors in India is allegedly a widespread practice

By Ed Silverman

Pharmalot

Now traces of a possible carcinogen have been found in a popular diabetes drug

By Ed Silverman

Pharmalot

Pharmalittle: Biotech CEOs tell Congress to nix Democrats’ drug pricing bill; pharma layoffs mounting

By Ed Silverman

Pharmalot

What side effects? Problems with medicines may be vastly underreported to the FDA

By Ed Silverman

Pharmalot

A second drug maker admits to price fixing as part of a far-reaching probe into generics

By Ed Silverman

Pharmalot

Pharmalittle: White House claims Dem pricing bill will yield 100 fewer drugs; trade deal may remove some biologic protections

By Ed Silverman

Pharmalot

As Trump looks overseas for drug pricing ideas, one expert says France has some useful approaches

By Ed Silverman

Pharmalot

Pharmalittle: Richard Sackler pushed to downplay OxyContin risks; Trump may scale back pharma protection in trade deal

By Ed Silverman

Pharmalot

Pharmalittle: China to bulk-buy to lower drug costs; Senate bill to tackle drug prices going nowhere fast

By Ed Silverman

Pharmalot

Biogen will offer discounts to a health plan if patients say its multiple sclerosis drugs don’t work

By Ed Silverman

Pharmalot

Pharmalittle: Feds probe drug makers for flooding communities with opioids; States proceeding with importation

By Ed Silverman

Pharmalot

EMA adopts EU Ombudsman recommendations to avoid bias concerns over drug approvals

By Ed Silverman

Pharmalot

Pharmalittle: Generic makers talk to feds about ending price-fixing probe; how the Arnolds fueled the pricing debate in D.C.

By Ed Silverman

Amid fears of superbugs, sales of antibiotics used in food-producing livestock rose last year

Up and down the ladder: The latest comings and goings

Pharmalittle: FDA does about-face on rare disease drug; patent office pulls lawyer from Gilead case

U.S. Patent Office removes lawyer from high-profile case involving a Gilead HIV medicine

PhRMA sues Oregon over drug pricing transparency laws, calling them ‘unconstitutional’

Activists say a patent office lawyer’s tweets showed ‘bias’ in favor of Gilead in HIV drug case

Pharmalittle: Pharma ad spend skyrockets to defeat drug pricing bill; many antibiotic prescriptions are inappropriate

Pharmalittle: Drug factories ‘dump it down the drain’; breast cancer drug picked up by AstraZeneca shrinks tumors

GAO finds ongoing problems with FDA inspections of foreign drug facilities

Pharmalittle: A record-setting year for biopharma M&A; Pelosi tries to stem revolt over drug pricing bill

Pharmalittle: Republicans have new drug pricing proposal; Sanofi and Merck buy cancer drug companies

Lawmakers ask HHS for greater oversight of patient assistance programs

More hospital drug spending is going toward cancer immunotherapies

Up and down the ladder: The latest comings and goings

Pharmalittle: Retail prices for drugs edged down last year; Biogen Alzheimer’s data prompt skepticism

Activists seek to block a Gilead patent extension on a lucrative HIV drug

Bribing doctors in India is allegedly a widespread practice

Now traces of a possible carcinogen have been found in a popular diabetes drug

Pharmalittle: Biotech CEOs tell Congress to nix Democrats’ drug pricing bill; pharma layoffs mounting

What side effects? Problems with medicines may be vastly underreported to the FDA

A second drug maker admits to price fixing as part of a far-reaching probe into generics

Pharmalittle: White House claims Dem pricing bill will yield 100 fewer drugs; trade deal may remove some biologic protections

As Trump looks overseas for drug pricing ideas, one expert says France has some useful approaches

Pharmalittle: Richard Sackler pushed to downplay OxyContin risks; Trump may scale back pharma protection in trade deal

Pharmalittle: China to bulk-buy to lower drug costs; Senate bill to tackle drug prices going nowhere fast

Biogen will offer discounts to a health plan if patients say its multiple sclerosis drugs don’t work

Pharmalittle: Feds probe drug makers for flooding communities with opioids; States proceeding with importation

EMA adopts EU Ombudsman recommendations to avoid bias concerns over drug approvals

Pharmalittle: Generic makers talk to feds about ending price-fixing probe; how the Arnolds fueled the pricing debate in D.C.